Search Results - "Oettle, H."

α-Smooth muscle actin expression and desmoplastic stromal reaction in pancreatic cancer: results from the CONKO-001 study by Sinn, M, Denkert, C, Striefler, J K, Pelzer, U, Stieler, J M, Bahra, M, Lohneis, P, Dörken, B, Oettle, H, Riess, H, Sinn, B V

“…Background: Previous investigations in pancreatic cancer suggest a prognostic role for α -smooth muscle actin ( α -SMA) expression and stromal density in the…”
Get full text

Consensus in determining the resectability of locally progressed pancreatic ductal adenocarcinoma - results of the Conko-007 multicenter trial by Wittel, U A, Lubgan, D, Ghadimi, M, Belyaev, O, Uhl, W, Bechstein, W O, Grützmann, R, Hohenberger, W M, Schmid, A, Jacobasch, L, Croner, R S, Reinacher-Schick, A, Hopt, U T, Pirkl, A, Oettle, H, Fietkau, R, Golcher, H

“…One critical step in the therapy of patients with localized pancreatic cancer is the determination of local resectability. The decision between primary surgery…”
Get full text

Phase III Trial of Gemcitabine Plus Tipifarnib Compared With Gemcitabine Plus Placebo in Advanced Pancreatic Cancer by VAN CUTSEM, E, VAN DE VELDE, H, SAFRAN, H, HUMBLET, Y, PEREZ RUIXO, J, MA, Y, VON HOFF, D, KARASEK, P, OETTLE, H, VERVENNE, W. L, SZAWLOWSKI, A, SCHOFFSKI, P, POST, S, VERSLYPE, C, NEUMANN, H

“…To determine whether addition of the farnesyltransferase inhibitor tipifarnib (Zarnestra, R115777; Johnson and Johnson Pharmaceutical Research and Development,…”
Get full text

CONKO-006: A randomised double-blinded phase IIb-study of additive therapy with gemcitabine + sorafenib/placebo in patients with R1 resection of pancreatic cancer – Final results by Sinn, M., Liersch, T., Riess, H., Gellert, K., Stübs, P., Waldschmidt, D., Lammert, F., Maschmeyer, G., Bechstein, W., Bitzer, M., Denzlinger, C., Hofheinz, R., Lindig, U., Ghadimi, M., Hinke, A., Striefler, J.K., Pelzer, U., Bischoff, S., Bahra, M., Oettle, H.

“…CONKO-006 was designed for patients with pancreatic adenocarcinoma with postsurgical R1 residual status to evaluate the efficacy and safety of the combination…”
Get full text

R0 resection following chemo (radio)therapy improves survival of primary inoperable pancreatic cancer patients. Interim results of the German randomized CONKO-007± trial by Fietkau, R., Grützmann, R., Wittel, U. A., Croner, R. S., Jacobasch, L., Neumann, U. P., Reinacher-Schick, A., Imhoff, D., Boeck, S., Keilholz, L., Oettle, H., Hohenberger, W. M., Golcher, H., Bechstein, W. O., Uhl, W., Pirkl, A., Adler, W., Semrau, S., Rutzner, S., Ghadimi, M., Lubgan, D.

“…Purpose Chemotherapy with or without radiotherapy is the standard in patients with initially nonmetastatic unresectable pancreatic cancer. Additional surgery…”
Get full text

SPARC expression in resected pancreatic cancer patients treated with gemcitabine: results from the CONKO-001 study by Sinn, M., Sinn, B.V., Striefler, J.K., Lindner, J.L., Stieler, J.M., Lohneis, P., Bischoff, S., Bläker, H., Pelzer, U., Bahra, M., Dietel, M., Dörken, B., Oettle, H., Riess, H., Denkert, C.

“…Previous investigations in pancreatic cancer suggested a prognostic role for secreted protein acidic and rich in cysteine (SPARC) expression in the peritumoral…”
Get full text

Human equilibrative nucleoside transporter 1 expression analysed by the clone SP 120 rabbit antibody is not predictive in patients with pancreatic cancer treated with adjuvant gemcitabine – Results from the CONKO-001 trial by Sinn, M, Riess, H, Sinn, B.V, Stieler, J.M, Pelzer, U, Striefler, J.K, Oettle, H, Bahra, M, Denkert, C, Bläker, H, Lohneis, P

“…Abstract Background High expression of human equilibrative nucleoside transporter 1 (hENT1) is considered to predict survival in patients treated with adjuvant…”
Get full text

A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer by Oettle, H., Richards, D., Ramanathan, R. K., van Laethem, J. L., Peeters, M., Fuchs, M., Zimmermann, A., John, W., Von Hoff, D., Arning, M., Kindler, H. L.

“…Background: This randomized phase III study compared the overall survival (OS) of pemetrexed plus gemcitabine (PG) versus standard gemcitabine (G) in patients…”
Get full text

Capecitabine plus oxaliplatin as first-line treatment in patients with advanced biliary system adenocarcinoma: a prospective multicentre phase II trial by Nehls, O, Oettle, H, Hartmann, J T, Hofheinz, R-D, Hass, H G, Horger, M S, Koppenhöfer, U, Hochhaus, A, Stieler, J, Trojan, J, Gregor, M, Klump, B

“…This prospective multicentre phase II study characterises the toxicity and activity of first-line capecitabine and oxaliplatin combination therapy (CAPOX) in…”
Get full text

Corrections to “SPARC expression in resected pancreatic cancer patients treated with Gemcitabine: results from the CONKO-001 study” by Sinn, M., Sinn, B.V., Striefler, J.K., Lindner, J.L., Stieler, J.M., Lohneis, P., Bischoff, S., Bläker, H., Pelzer, U., Bahra, M., Dietel, M., Dörken, B., Oettle, H., Riess, H., Denkert, C.

Get full text

SPARC expression in resected pancreatic cancer patients treated with Gemcitabine: results from the CONKO-001 study by Sinn, M, Sinn, B V, Striefler, J K, Lindner, J L, Stieler, J M, Lohneis, P, Bischoff, S, Bläker, H, Pelzer, U, Bahra, M, Dietel, M, Dörken, B, Oettle, H, Riess, H, Denkert, C

Get full text

PD-007CXCR4, CXCR7 and CXCL12 expression is not a prognostic predictive factor in patients with resected pancreatic cancer - results from the CONKO-001 trial by Striefler, J, Wislocka, L, Sinn, M, Pelzer, U, Denkert, C, Juehling, A, Bischoff, S, Bahra, M, Hendrik, B, Oettle, H, Riess, H, Lohneis, P

Get full text

Detection of Ki-ras mutations in tissue and plasma samples of patients with pancreatic cancer using PNA-mediated PCR clamping and hybridisation probes by DÄBRITZ, J, HÄNFLER, J, PRESTON, R, STIELER, J, OETTLE, H

“…In the present study, we combined the PCR-clamping approach with melting curve analysis using mutant specific hybridisation probes and wild-type specific…”
Get full text

Randomized double-blind phase II trial comparing gemcitabine plus LY293111 versus gemcitabine plus placebo in advanced adenocarcinoma of the pancreas by Saif, Muhammad Wasif, Oettle, H, Vervenne, W L, Thomas, J P, Spitzer, G, Visseren-Grul, C, Enas, N, Richards, D A

“…LY293111 (LY) is a novel oral anticancer agent with leukotriene B4 receptor antagonist and peroxisome proliferator-activated receptor gamma agonist properties,…”
Get full text

S3-guideline exocrine pancreatic cancer by Seufferlein, T, Porzner, M, Becker, T, Budach, V, Ceyhan, G, Esposito, I, Fietkau, R, Follmann, M, Friess, H, Galle, P, Geissler, M, Glanemann, M, Gress, T, Heinemann, V, Hohenberger, W, Hopt, U, Izbicki, J, Klar, E, Kleeff, J, Kopp, I, Kullmann, F, Langer, T, Langrehr, J, Lerch, M, Löhr, M, Lüttges, J, Lutz, M, Mayerle, J, Michl, P, Möller, P, Molls, M, Münter, M, Nothacker, M, Oettle, H, Post, S, Reinacher-Schick, A, Röcken, C, Roeb, E, Saeger, H, Schmid, R, Schmiegel, W, Schoenberg, M, Siveke, J, Stuschke, M, Tannapfel, A, Uhl, W, Unverzagt, S, van Oorschot, B, Vashist, Y, Werner, J, Yekebas, E

Get more information

Gemcitabine in combination with 5‐fluorouracil with or without folinic acid in the treatment of pancreatic cancer by Oettle, Helmut, Riess, Hanno

“…Pancreatic cancer is one of the most frequently reported gastrointestinal tumors and has been reported to have a 5‐year survival rate of < 5%. It is most…”
Get full text

Hematopoietic rescue after high-dose chemotherapy using autologous peripheral-blood progenitor cells or bone marrow: a randomized comparison by Beyer, J, Schwella, N, Zingsem, J, Strohscheer, I, Schwaner, I, Oettle, H, Serke, S, Huhn, D, Stieger, W

“…To compare autologous bone marrow (BM) with peripheral-blood progenitor cells (PBPC) as hematopoietic rescue after high-dose chemotherapy (HDCT). From January…”
Get more information

8032 POSTER Catumaxomab Administered as a 3-hour Infusion – Results From a Newly Integrated Safety Analysis Comprising 7 Clinical Studies by Finas, D, Schmalfeldt, B, Schilling, J, Oettle, H, Hennig, M, Ligensa, T, Schlegel, C, Seimetz, D, Kainz, A

Get full text

1233 POSTER Phase l/lI Study With Trabedersen (AP 12009) Monotherapy for the Treatment of Patients With Advanced Pancreatic Cancer, Malignant Melanoma or Colorectal Carcinoma by Schlinqensiepen, K, Oettle, H, Seufferlein, T, Luger, T, Schmid, R.M, von Wiehert, G, Endlicher, E, Garbe, C, Kaehler, K.C, Enk, A

Get full text

Therapie des metastasierten Pankreaskarzinoms by Ettrich, T.J., Oettle, H., Seufferlein, T.

“…Zusammenfassung Hintergrund Das duktale Adenokarzinom des Pankreas ist eine relativ häufige tumorbedingte Todesursache in westlichen Industrienationen. Da…”
Get full text